Performance of REGN Regeneron Pharmaceuticals | 17.4% in 12m
Compare REGN with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Regeneron Pharmaceuticals with its related Sector/Index XBI
Performance Duell REGN vs XBI
| TimeFrame | REGN | XBI |
|---|---|---|
| 1 Day | 3.78% | 1.16% |
| 1 Week | 5.27% | 7.44% |
| 1 Month | -1.79% | -2.58% |
| 3 Months | -0.80% | 0.42% |
| 6 Months | 14.5% | 29.44% |
| 12 Months | 17.4% | 10.82% |
| YTD | 3.60% | -2.09% |
| Rel. Perf. 1m | 0.10 | |
| Rel. Perf. 3m | 0.37 | |
| Rel. Perf. 6m | -1.21 | |
| Rel. Perf. 12m | 0.72 |
Is Regeneron Pharmaceuticals a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Regeneron Pharmaceuticals (NASDAQ:REGN) is currently (May 2024)
a good stock to buy. It has a ValueRay Fundamental Rating of 68.36 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of REGN as of May 2024 is 988.22. This means that REGN is currently overvalued and has a potential downside of 5.4% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of REGN as of May 2024 is 988.22. This means that REGN is currently overvalued and has a potential downside of 5.4% (Sold with Premium).
Is REGN a buy, sell or hold?
- Strong Buy: 11
- Buy: 8
- Hold: 6
- Sell: 3
- Strong Sell: 0
Values above 0%: REGN is performing better - Values below 0%: REGN is underperforming
Compare REGN with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 4.96% | 0.87% | -3.57% | -7.28% |
| US NASDAQ 100 | QQQ | 4.69% | 1.43% | -3.40% | -17.13% |
| US Dow Jones Industrial 30 | DIA | 4.93% | 0.56% | 0.50% | 1.77% |
| German DAX 40 | DBXD | 5.46% | 0.49% | -3.34% | 4.29% |
| UK FTSE 100 | ISFU | 3.99% | -4.51% | -0.04% | 7.88% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 0.34% | -5.14% | 9.88% | 27.38% |
| Hongkong Hang Seng | HSI | -1.60% | -7.99% | 14.01% | 31.90% |
| Japan Nikkei 225 | EXX7 | 2.91% | 3.57% | 0.64% | -2.37% |
| India NIFTY 50 | INDA | 3.95% | -4.52% | -6.37% | -11.85% |
| Brasil Bovespa | EWZ | 2.12% | -1.07% | 10.18% | -5.95% |
REGN Regeneron Pharmaceuticals vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 3.46% | 1.61% | -5.39% | -18.86% |
| Consumer Discretionary | XLY | 3.90% | -0.06% | 2.22% | -4.09% |
| Consumer Staples | XLP | 5.40% | -2.17% | 2.69% | 16.69% |
| Energy | XLE | 9.48% | 2.23% | 6.92% | -1.51% |
| Financial | XLF | 6.30% | 1.11% | -7.90% | -9.95% |
| Health Care | XLV | 4.87% | 0.78% | 2.81% | 10.59% |
| Industrial | XLI | 5.71% | 0.21% | -7.59% | -7.17% |
| Materials | XLB | 5.65% | 2.22% | -0.96% | 3.98% |
| Real Estate | XLRE | 4.45% | 2.58% | 5.55% | 13.95% |
| Technology | XLK | 5.54% | 2.94% | -1.85% | -15.45% |
| Utilities | XLU | 3.85% | -5.63% | 2.19% | 14.58% |
| Aerospace & Defense | XAR | 2.44% | -2.81% | -1.24% | -3.65% |
| Biotech | XBI | -2.17% | 0.79% | -14.93% | 6.61% |
| Homebuilder | XHB | 4.24% | 2.22% | -23.25% | -31.07% |
| Retail | XRT | 4.88% | 3.14% | -6.44% | -3.58% |
Does Regeneron Pharmaceuticals outperform its market, is REGN a Sector Leader?
Yes, over the last 12 months Regeneron Pharmaceuticals (REGN) made 17.43%, while its related Sector, the SPDR S&P Biotech (XBI) made 10.82%.
Over the last 3 months REGN made -0.80%, while XBI made 0.42%.
Yes, over the last 12 months Regeneron Pharmaceuticals (REGN) made 17.43%, while its related Sector, the SPDR S&P Biotech (XBI) made 10.82%.
Over the last 3 months REGN made -0.80%, while XBI made 0.42%.
| Period | REGN | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -1.79% | -2.58% | -2.66% |
| 3 Months | -0.80% | 0.42% | 2.48% |
| 12 Months | 17.43% | 10.82% | 24.71% |